All News

Anti-tumor necrosis factor (TNF) agents were the most commonly prescribed bDMARDs in this cohort.

The FDA will address new ways to increase the availability of naloxone, during a 2-day advisory committee meeting in December.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older.

The FDA has approved dupilumab (Dupixent®, Regeneron and Sanofi) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.

Phase 2 data for evobrutinib shows reduction in lesions and relapse rates in patients with multiple sclerosis.

Top news of the day from across the health care landscape.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

CDC officials note that it is safe to be around infants and young children, pregnant women, or people with weakened immune systems after you get the shingles vaccine.

The updated label changes include information regarding use of rituximab as a follow up treatment in adults with 2 rare forms of vasculitis.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Want to increase cash flow and profits? And create more wealth in the process? There are 3 powerful tools to accomplish that.

Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.

Top news of the day from across the health care landscape.

A combination of next generation broadly neutralizing antibodies might be able to achieve long-term viral suppression of HIV without the need for a daily antiretroviral pill, according to recently published research.

Top news of the week from Specialty Pharmacy Times.

Mylan announced Thursday it has launched Medroxyprogesterone Acetate (MPA) Injectable Suspension USP, 150 mg/mL Single-Dose Vial in the United States for the prevention of pregnancy.

This digital technology allows patients to have meaningful conversations with pharmacists from their homes.

The investigational therapy olaparib (Lynparza, AstraZeneca and Merck) has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of pancreatic cancer, according to an AstraZeneca press release.

Provider-centric stigma reduction interventions can help reduce stigmatizing behaviors towards patients with HIV and potentially improve care, according to a new systematic review from the CDC.

Clinical trial demonstrates adoptive T-cell therapy may be successful in treating progressive multifocal leukoencephalopathy.

California’s tobacco control programs have lowered lung cancer deaths 33% faster than the rest of the United States.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

Top news of the day from across the health care landscape.